Pfizer Inc.’s recent disclosure that it would be raising list prices on some of its prescription drugs next year is a case in point on why the current system of rebates must change, HHS Deputy Secretary Eric Hargan pointed out during the FDA/CMS Summit in Washington D.C. Dec. 12.
Pfizer announced in November that it would increase prices on 41 drugs, representing 10% of its portfolio, in mid-January. Increases...